Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CBD oil under study for Tough-to-Treat seizures

NCT ID NCT07233239

Symptom relief Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 12, 2026 · Updated 4 times

Summary

This study tests a liquid form of cannabidiol (CBD) in 100 people aged 12 to 75 who have focal-onset seizures. CBD is already approved for certain rare seizure disorders, and researchers want to see if it can also help reduce focal seizures. Participants will take CBD oil by mouth, and doctors will track changes in seizure frequency and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cannabidiol oral solution (CBD oil)
What this could lead to
If successful, this could provide a new treatment option for people with focal-onset seizures who don't respond well to current medications.
What could go wrong
This is an early-phase, small trial (100 people) with no placebo group, so results may not be conclusive. CBD can cause side effects like drowsiness or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants are eligible to be included in the main study only if all of the following criteria apply: 1. Participant has a documented diagnosis of focal epilepsy according to the ILAE Classification of Epilepsy, 2017, characterized by focal seizure types with typical interictal/ictal EEG findings (eg, history of an EEG with focal sharp waves or slowing). Participants with a documented diagnosis of focal epilepsy and a normal EEG are eligible for inclusion. 2. Participant is currently treated with at least 1, but no more than 4, antiseizure medications on a stable regimen. 3. Participant is aged 12 to 75 years old, inclusive, at Screening. Participants are excluded from the study if any of the following criteria apply: 1. Has a concurrent, confirmed diagnosis of non-epileptic seizures or events that can confound the assessment of the efficacy measures, in the opinion of the investigator. 2. Has clinically significant unstable medical condition(s), other than epilepsy. 3. History of suicidal behavior, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to Item 4 or Item 5 on the C-SSRS or is considered at risk of suicide or self-harm based on the clinical judgement of the investigator following interview with the participant and/or caregiver. 4. Has known or suspected hypersensitivity to cannabinoids or any of the excipients of the study intervention, such as sesame oil. 5. Is currently treated with Epidiolex or received treatment with Epidiolex within 28 days prior to Screening (Visit 1). 6. Is currently using or has used recreational or medicinal cannabis, cannabinoid/CBD based medications, products, or supplements (botanical or synthetic) within 28 days prior to Screening (Visit 1) and/or is unwilling to abstain for the duration of the study. 7. Presence of only nonmotor focal aware seizures or primary generalized epilepsies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Focal seizures are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

focal epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focal seizures

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ANESC Research

    RECRUITING

    El Paso, Texas, 79912, United States

  • Banner University Medical Center-Phoenix

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85006, United States

  • Boston Children's Health Physicians

    RECRUITING

    Hawthorne, New York, 10532, United States

  • Child Neurology & Consultants of Austin

    RECRUITING

    Austin, Texas, 78757, United States

  • Cincinnati Children's Hospital

    RECRUITING

    Cincinnati, Ohio, 45229, United States

  • Corewell Health

    NOT_YET_RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • Emory University

    RECRUITING

    Atlanta, Georgia, 30329, United States

  • Hackensack Meridian Neuroscience Institute at JFK University Medical Center

    NOT_YET_RECRUITING

    Edison, New Jersey, 08820, United States

  • Intermountain Health

    RECRUITING

    Murray, Utah, 84107, United States

  • Le Bonheur Children's Hospital

    RECRUITING

    Memphis, Tennessee, 38103, United States

  • Mid-Atlantic Epilepsy and Sleep Center

    RECRUITING

    Bethesda, Maryland, 20817, United States

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Onsite Clinical Solutions

    RECRUITING

    Charlotte, North Carolina, 28211, United States

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

  • Saint Peter's University Hospital

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Savannah Neurology Specialists

    RECRUITING

    Savannah, Georgia, 31406, United States

  • Seattle Children's Hospital

    RECRUITING

    Seattle, Washington, 98105, United States

  • UC San Diego

    RECRUITING

    La Jolla, California, 92037-1300, United States

  • University of Cincinnati, Gardner Neuroscience Institute

    RECRUITING

    Cincinnati, Ohio, 45267-0525, United States

  • University of South Florida

    RECRUITING

    Tampa, Florida, 33606, United States

  • Velocity Clinical Research at Raleigh Neurology

    RECRUITING

    Raleigh, North Carolina, 27607, United States

  • Wayne State University

    RECRUITING

    Detroit, Michigan, 48201, United States

  • William S Middleton Memorial Veterans Hospital

    NOT_YET_RECRUITING

    Madison, Wisconsin, 53705, United States

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06510, United States